New Technologies for Sustainable Oligonucleotide Manufacture
Symposium Organizer: Ben Andrews, Investigator, GSK
Co-Sponsor: ACS Green Chemistry Institute Pharmaceutical Roundtable
Oligonucleotides are gaining traction as a new therapeutic modality with 12 products approved for use and many more following on. However, these compounds face significant sustainability issues, the chief of which is the large amount of waste generated during manufacture (4300 kg waste per kg of drug substance produced). Several new technologies are in development to address these issues such as solution phase chemistry, P(V) chemistry, solvent recovery, enzyme catalysed synthesis and alternative purification techniques to name but a few. The aim of this session is to highlight some of the recent developments in these areas and the potential benefits they bring to oligonucleotide sustainability. We invite abstracts on the topic of improving oligonucleotide sustainability from interested parties in academia and industry.